Acanthamoeba Keratitis Management Review Highlights Biguanide Monotherapy Efficacy and Emerging Therapies
Background
Acanthamoeba keratitis (AK) is a rare but increasingly prevalent and sight-threatening corneal infection, primarily linked to contact lens use. Current management is challenging due to limited therapeutic options, variable clinical responses, and a significant lack of standardized treatment guidelines. Diagnosis is often delayed by non-specific symptoms, and early corticosteroid use can worsen outcomes. The formation of highly drug-resistant cysts in chronic infections further complicates treatment, necessitating prolonged, often empirical, combination therapies.
Study Design
This comprehensive review synthesized current literature on the medical and surgical management of Acanthamoeba keratitis (AK). Researchers conducted a PubMed search using terms like keratitis or corneal ulcer combined with treatment, therapy, therapeutic, or management. Articles describing conventional antimicrobial-based treatments were specifically excluded to focus on advanced and novel approaches. The review aimed to provide an up-to-date overview of existing and emerging interventions, highlighting current challenges and future directions in AK management.
Results
The review found that prolonged combination therapy with topical biguanides and aromatic diamidines remains the mainstay for Acanthamoeba keratitis (AK). However, recent evidence supports topical biguanide monotherapy (in higher concentrations) achieving comparable outcomes to traditional combination treatment. Adjunctive therapies, including azoles, miltefosine, and corticosteroids, were identified as potentially beneficial for refractory disease, though their use is often empirical. Surgical interventions such as therapeutic keratoplasty are frequently required in advanced or non-responsive cases.
The review highlighted promising emerging therapeutic approaches, including antimicrobial peptides, synthetic polymers, bioactive natural compounds, and ultraviolet C therapy, as potential alternatives for more effective or better-tolerated treatment. Diagnosis delays due to non-specific presentation and the formation of highly drug-resistant cysts in chronic infection were identified as key challenges complicating management.
Key Findings
- Topical biguanide monotherapy (at higher concentrations) shows comparable outcomes to traditional combination therapy for AK.
- Adjunctive therapies like azoles, miltefosine, and corticosteroids may benefit refractory AK cases.
- Surgical interventions, including therapeutic keratoplasty, are often necessary for advanced or non-responsive AK.
- Emerging therapies, including antimicrobial peptides and UV-C, show promise for more effective AK treatment.
Why It Matters
This review provides a critical update for clinicians and researchers grappling with Acanthamoeba keratitis, suggesting a potential shift towards topical biguanide monotherapy as a viable, simpler alternative to combination regimens. For peptide users and biohackers, the mention of antimicrobial peptides as an emerging therapeutic avenue signals future potential for novel, targeted interventions. The emphasis on individualized, evidence-based strategies underscores the need for more rigorous clinical trials to establish standardized protocols, moving beyond current empirical approaches. This could lead to more effective and less toxic treatments, improving patient outcomes and potentially shortening treatment durations.
acanthamoeba keratitis
corneal infection
antimicrobial peptides
biguanides
miltefosine
review